Pharma major Lupin announced today that it has received establishment inspection reports (EIR) for its Mandideep and Aurangabad facilities wherein the USFDA has concluded that the inspections stand closed.
The US FDA had conducted audits at Lupin's Mandideep facility from February 8 to 19, 2016 and its Aurangabad facility from January 11 to 15, 2016.
''Having received the EIRs from the US FDA about the closure of these inspections, all observations stand addressed, and both these facilities are cGMP compliant,'' said the company.
Earlier, the company had taken appropriate steps to address the observations it had received from these audits.
Shares of the company gained Rs 35.45, or 2.41%, to trade at Rs 1,505.55. The total volume of shares traded was 186,959 at the BSE (11.59 a.m., Friday).